Reporter nanoparticle that monitors its anticancer efficacy in real time

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

| As Published | http://dx.doi.org/10.1073/pnas.1603455113 |
| Publisher | National Academy of Sciences (U.S.) |
| Version | Final published version |
| Citable link | http://hdl.handle.net/1721.1/106793 |
| Terms of Use | Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use. |
The ability to monitor the efficacy of an anticancer treatment in real time can have a critical effect on the outcome. Currently, clinical readouts of efficacy rely on indirect or anatomic measurements, which occur over prolonged time scales postchemotherapy or postimmunotherapy and may not be concordant with the actual effect. Here we describe the biology-inspired engineering of a simple 2-in-1 reporter nanoparticle that not only delivers a cytotoxic or an immunotherapy payload to the tumor but also reports back on the efficacy in real time. The reporter nanoparticles are engineered from a novel two-staged stimuliresponsive polymeric material with an optimal ratio of an enzyme-cleavable drug or immunotherapy (effector elements) and a drug function-activatable reporter element. The spatiotemporally constrained delivery of the effector and the reporter elements in a single nanoparticle produces maximum signal enhancement due to the availability of the reporter element in the same cell as the drug, thereby effectively capturing the temporal apoptosis process. Using chemotherapy-sensitive and chemotherapy-resistant tumors in vivo, we show that the reporter nanoparticles can provide a real-time noninvasive readout of tumor response to chemotherapy. The reporter nanoparticle can also monitor the efficacy of immune checkpoint inhibition in melanoma. The self-reporting capability, for the first time to our knowledge, captures an anticancer nanoparticle in action in vivo.

Significance
The ability to identify responders and nonresponders very early during chemotherapy by direct visualization of the activity of the anticancer treatment and to switch, if necessary, to a regimen that is effective can have a significant effect on the outcome as well as quality of life. Current approaches to quantify response rely on imaging techniques that fail to detect very early responses. In the case of immunotherapy, the early anatomical readout is often discordant with the biological response. This study describes a self-reporting nanomedicine that not only delivers chemotherapy or immunotherapy to the tumor but also reports back on its efficacy in real time, thereby identifying responders and nonresponders early on.


Reviewers: A.M., University of Texas MD Anderson Cancer Center; and W.Z., University of California, Irvine.

The authors declare no conflict of interest.

1To whom correspondence may be addressed. Email: ashishk@mit.edu, ram@ncl.res.in, or shiladit@mit.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1603455113/-/DCSupplemental.
a therapeutic that was activated inside the tumor by matrix metalloproteinase enzymes and thereby reduced off-target toxicity (29).

However, despite the advances in the use of nanomaterials for drug delivery, in molecular imaging, and in theranostics, there are currently no nanomaterials that merge the advantages of improved efficacy with the ability to self-monitor the anticancer activity in vivo. Here we describe the design of a stimuli-responsive polymeric nanostructure, which we term a “reporter nanoparticle,” comprising a polymeric backbone conjugated to a cytotoxic chemotherapeutic agent or an immunotherapy agent as an effector element and an enzyme-activatable reporter element engineered from a quenched fluorescent dye (Fig. 1). We demonstrate that such a reporter nanoparticle can start emitting a signal as early as 8 h posttreatment in the case of chemotherapy and can facilitate the distinction between responsive and resistant tumors in vivo. Additionally, it can be used to detect the efficacy of immune checkpoint inhibition at time points not accessible with current anatomic- or metabolic-based detection techniques. A reporter nanoparticle not only can emerge as a powerful platform for enhancing the efficacy of chemotherapy but additionally can provide a real-time noninvasive read out of tumor response to therapy.

**Fig. 1.** Schematic showing construct of a reporter nanoparticle. The reporter nanoparticle comprises three components: a polymeric backbone, an esterase-cleavable produg synthesized from an anticancer drug [effector element (EE)], and an activatable reporter element (RE). At the optimal ratio of EE:RE, this stimuli-responsive polymer self-assembles into a nanoparticle. The reporter element is a caspase-3-cleavable sequence consisting of l-amino acids GKDDEVADPC-CONH₂ to which we conjugated a FRET pair such that cleavage of the DEVD sequence results in removal of the quenching of the fluorescent signal. The effector element is conjugated to the polymeric backbone via an esterase-cleavable bond, whereas the reporter element is conjugated via an amide bond with the Gly residue. In normal condition, the fluorescent signal from the reporter element is in the off state because the drug is intact inside the nanoparticle. The nanoparticles home in to the tumor via the EPR effect, where the nanoparticle is internalized by cancer cell. In a drug-sensitive cell (lower right of schematic), the released drug initiates apoptosis via the activation of caspase-3 enzyme, which then cleaves the DEVD peptide, unquenching the fluorescent signal (on state). However, in a nonresponder cell (lower left), the failure of the released drug to induce apoptosis means the reporter element remains in the off state. This distinction between off and on states allows the visualization of a nanoparticle in action.

**Results**

**Design and Synthesis of the Reporter and Effector Components of the Reporter Nanoparticle.** It is well established that downstream apoptotic responses determine therapeutic outcomes (30, 31), and apoptosis defects can contribute to drug resistance (32). Similarly, the ligation of PD-L1 on cancer cells by immune checkpoint inhibitors was shown to induce apoptosis (33). Both intrinsic and extrinsic apoptotic pathways converge into caspases, a family of cysteine proteases, which are known to cleave precise substrates (34). Indeed, the activation of caspases has been extensively used to monitor cell death (35–37). We rationalized that the pathophysiological caspase activation in a drug-responsive tumor following the release of the cytotoxic effector could be used to trigger the cleavage of a quenched dye in the design of the reporter nanoparticle. The subsequent increase in the signal readout could serve as a direct real-time quantification of chemotherapy or immunotherapy efficacy (Fig. 1).

As a proof of concept, we used paclitaxel, a well-established cytotoxic chemotherapy agent that activates caspase (38), as the effector element, whereas the reporter element was designed using a short peptide containing a caspase-3-cleavable Asp-Glu-Val-Asp (DEVD) sequence inserted between either the Förster resonance energy transfer (FRET) pair of 5-FAM (visible-range fluorophore) and QSY-7 (quencher) or the pair of DyLight 755 (near-infrared fluorophore) and DyLight 766Q (quencher), where the latter pair enabled in vivo imaging. Indeed, previous studies have shown that caspase-based cleavage of the peptide bond can be used to activate fluorescence in self-quenched systems (39, 40). We used poly(isobutylene-alt-maleic anhydride) (PIMA), a low-molecular weight (6 kDa) polymer, as the template to engineer the stimuli-responsive material. PIMA contains reactive anhydride functional groups that can be easily conjugated to a wide range of drugs and other reactive moieties under mild reaction conditions and can be used for conjugating more than one agent for multiplexing studies. Recently, we reported that the coordination complex between platinum (II) and PIMA could enable the self-assembly into nanostructures that exhibited greater antitumor efficacy with reduced systemic toxicity compared with cisplatin (41, 42).

We first synthesized the FRET pair-based reporter element. The near-infrared (NIR) FRET pair of fluorophore, DyLight 755, and quencher, DyLight 766Q, was chosen for fabricating the reporter element for several reasons. First, DyLight 755 NIR fluorescent dye belongs to the polymethine carbocyanine family of dyes, and DyLight 766Q belongs to benzopyrillium-based quencher dyes, which have been widely used for their excellent spectral properties and biocompatibility. Second, for efficient in vivo imaging using an activatable probe for monitoring enzymatic activity, it is highly desirable to maximize signal-to-noise ratio by having no background fluorescence before and maximal fluorescence signal after activation. Hence, we used a nonfluorescent quencher, which will not have any interference post-enzymatic activation of the reporter element. Third, excellent spectral overlap of donor fluorescence (emission maxima 776 nm) and quencher absorbance (λmax 766 nm) ensured maximum quenching efficiency at 1:1 donor:acceptor ratio. Furthermore, the dyes have reactive functional groups that can be used for easy conjugation to amino acids using different bioconjugation techniques. Also, an optimum peptide length was used to conjugate the FRET pair for maximum FRET efficiency (>90%). The fluorophore and the quencher were conjugated to the caspase substrate using maleimide and amide conjugation, respectively, on either side of DEVD peptide (Fig. S1). Similarly, we synthesized a reporter element using another FRET pair consisting of a green fluorescent dye (5-FAM) and quencher QSY-7, where the quenching efficiency was 94.7% (Fig. S2). The enzymatic susceptibility of the reporter element was examined by incubating the reporter element with recombinant active caspase-3 enzyme at 37 °C and
monitoring the time-dependent fluorescence activation. As shown in Fig. 2A, a sustained increase in the fluorescence intensity was observed with time, indicating cleavage of the peptide by the enzyme, resulting in a 31-fold increase in fluorescence intensity achieved after 4 h of incubation. Caspases are typically classified as initiators (caspase-8 and caspase-10 belonging to the extrinsic pathway and caspase-9 belonging to the intrinsic pathway) and effectors (caspase-3, caspase-6, and caspase-7), with the initiators converging into the effectors for an apoptotic outcome (43). Typically, the effectors have been shown to recognize the DEVD motif (44). To test the selectivity of different caspases for the reporter element, we incubated the reporter element with recombinant caspase-3, caspase-6, caspase-7, and caspase-9 and measured the NIR fluorescence intensity at different time points. As shown in Fig. 2B, caspase-3 induced the highest activation rate and preferential cleavage over caspase-7, whereas caspase-6 and caspase-9 exhibited very low activation rates, consistent with the earlier observations (44). Similar results were obtained in the case of the 5-FAM-QSY-7-based FRET pair-conjugated reporter element when incubated with caspase-3 enzyme, supporting the applicability of the reporter element platform for a series of FRET pairs with a broad emission range from green to NIR (Fig. S2).

We next synthesized the effector element by selectively conjugating a linker, 4′-[2-aminoethyl]amino]-4-oxobutanoic acid at the more reactive C-2′ OH group on the isoserine moiety of the C-13 side chain of paclitaxel (Fig. S3 A–E). Although modification of the C2 alcohol of paclitaxel is known to result in considerable loss of activity (45, 46), the use of an appropriate cleavable linker meant that the construct could be activated in the tumor cells as a result of esterase enzymatic activity. Additionally, a higher effector element to polymer ratio of 15:1 meant that the construct could be activated in the tumor cells as a result of esterase enzymatic activity. Furthermore, the previously optimized polymer to responsive elements ratio of 1:15 constrained the maximum number of effector elements that could be conjugated to the polymer backbone by minimizing steric hindrance. We then optimized the number of effector element molecules complexed to the polymer backbone by minimizing steric hindrance. At an effector element to polymer ratio of 15:1, we obtained uniform nanoparticles with a hydrodynamic diameter of 170 ± 18 nm (Fig. S3 F and G). It is well established that nanoparticles in this size range preferentially accumulate into tumors through the leaky vasculature via an enhanced permeability and retention (EPR) effect, thereby enhancing anticancer effect and reducing off-target toxicities (47).

**Fabricating a Reporter Nanoparticle.** We next studied the effect of varying the ratio of effector and reporter elements in the polymer construct on the nanoparticle self-assembly, while keeping the previously optimized polymer to responsive elements ratio of 1:15 constrained. As shown in Fig. 2C, a higher effector element to reporter element ratio resulted in nanoparticles of smaller average size but with high polydispersity index, which were stable for less than 24 h at 4 °C (Fig. S4). Nanoparticles of uniform size 186.8 ± 7.3 nm (hydrodynamic diameter) and desired stability were obtained at an optimal effector element and reporter element ratio of 14.5:0.5 per polymer (Fig. 2C). High-resolution transmission electron microscopy showed nanostructures of average particle size ~100 nm (Fig. 2D). The zeta potential of nanoparticles at pH 7.4 was measured to be −41.5 mV (Fig. 2E), corresponding to high colloidal stability of the reporter nanoparticles over time (Fig. 2F). The zeta potential of the nanoparticle was found to switch toward a more positive charge with decreasing pH (Fig. 2G). We next studied the release of paclitaxel from the nanoparticles as a function of pH. As shown in Fig. 2H, drug release was accelerated under acidic conditions. Reporter nanoparticles engineered from a 5-FAM-QSY-7-based reporter element with optimized polymer to reporter element ratio of 1:13.5 exhibited similar characteristics (Fig. S5).

**In Vitro Characterization of Reporter Nanoparticle.** We evaluated the in vitro efficacy of reporter nanoparticles using multiple cancer cell lines, including breast (4T1 and MDA-MB-231), ovarian (4306), and lung (LLC). As shown in Fig. 3A, the nanoparticles induced tumor cell kill across all of the cell lines, with IC50 values ranging from 21.7 ± 5.8 to 517.0 ± 4.2 nM. Although the potency of reporter nanoparticles at 48 h postincubation was lower compared with paclitaxel, we observed an increase in potency, i.e., shift of concentration–response curve to the left, with time (Fig. 3B), consistent with the temporal release of paclitaxel in the cells. To explore the possibility of using the reporter nanoparticles for temporal imaging of drug efficacy, we incubated cancer cells with different concentrations of reporter nanoparticles and monitored the change in fluorescence intensity. As shown in Fig. 3C, a concentration- and time-dependent increase in the fluorescence signal was observed, which correlated with the reduction in cell viability. Monitoring the internalization of FAM-tagged nanoparticles into the cancer cells revealed a temporal uptake of the nanoparticles.
via the endolysosomal pathway (Fig. 3D). Furthermore, a robust overlap between the signal from the reporter (FAM-QSY7) nanoparticle and cytoplasmic active caspase-3 was noted, suggesting that the nanoparticles can escape the lysosomal compartment and the released taxane could activate the apoptotic machinery. This is consistent with previous reports where nanoparticles that switch their zeta potential from negative to positive, as observed in the current study, were shown to escape the endolysosomal compartment (48). Additionally, minimal caspase-3 and FAM signal was evident in the case of control nanoparticles that lacked an effector element, which validated that the signal observed in the case of reporter nanoparticles originates as a function of drug-induced activation of caspase-3 leading to apoptosis (Fig. 3E).

**Efficiency of Reporter Nanoparticles in a 3D in Vitro System.** Recent studies have shown that in vitro 3D culture systems better mimic in vivo tumor microenvironment compared with 2D monolayer cultures. Such systems model drug penetration and also conserve distinct signaling mechanisms that can influence the response to drug treatment (49, 50). We therefore treated paclitaxel-sensitive DU-145 and paclitaxel-resistant DU-145TR prostate cancer cell-derived 3D spheroids with reporter nanoparticles (at ~20 μM paclitaxel equivalent) for 24 h. Z-stack reconstruction and images for DU145 spheroids showed activation of fluorescence signal even at a depth of 70 μm, indicating that the nanoparticles can penetrate into the core and induce cell death. In contrast, minimal signal was observed from DU-145TR spheroids, indicating that the reporter nanoparticle could distinguish between sensitive and resistant tumors. The absence of any signal from the resistant spheroids further validated the absence of nonspecific activation of the reporter element (Fig. 3F).

**Reporter Nanoparticles Enable an Early Efficacy Readout in Vivo.** To investigate if reporter nanoparticles enable the monitoring of drug response in real time in vivo, we injected multiple doses of reporter nanoparticles engineered with the NIR (Dylight)-based reporter element into 4T1 breast cancer-bearing mice and imaged the animals at different time points between the treatments (Fig. 4A). As shown in Fig. 4B–D, control nanoparticles, which carried the same dose of the reporter element but no paclitaxel, exhibited baseline fluorescence inside the tumor, demonstrating that nonspecific activation of the reporter element in the tumor microenvironment was minimal and that the construct did not exhibit any toxicity to cancer cells in the absence of the cytotoxic drug. In the case of reporter nanoparticles, a significant increase in the fluorescent signal was observed as early as 8 h, but not at 4 h, after the first dose compared with control nanoparticles (Fig. 4C and Fig. S6A and B). Although a reduction in the signal was evident at 24 h postadministration, subsequent injections of the reporter nanoparticles enhanced the signal, indicating a direct correlation with the presence of the drug. A detectable signal was observed even after 4 d of the last treatment, which supported the hypothesis that sustained drug release from nanoparticles can induce a prolonged apoptotic effect (Fig. 4C and D). In contrast, it was only by day 6 that a statistically significant separation of the tumor growth curves (anatomical quantification) between the reporter nanoparticles-treated and control nanoparticles-treated group was evident (Fig. 4E). In earlier studies, quenched fluorescent caspase substrate-based tracers have been used to detect apoptosis in vivo (37, 51, 52). As controls, we therefore included a separate group, where the animals were treated with a combination of free paclitaxel and the reporter element at a similar dose level to that in the reporter nanoparticles. In another group, the animals were treated with a combination of an effector nanoparticle (nanoparticle with only paclitaxel) and the reporter element. In both these control groups, fluorescence signal amplification was not detected in tumors in vivo or ex vivo (Fig. 4F and Fig. S6A and B). We further investigated if [18F]FDG-PET/CT imaging could similarly detect the early treatment response as achieved using the reporter nanoparticles. It is well established that a decrease in FDG uptake on PET correlates with
Real-time reporting of drug efficacy in an in vivo syngeneic breast cancer mouse model. (A) A schematic showing reporter nanoparticle treatment and imaging schedule. The 4T1 breast cancer-bearing animals were injected with control nanoparticles (NPs) or reporter NPs. The control NPs were synthesized by conjugation of reporter element to the polymer backbone without paclitaxel-based effector element. When the tumor volume reached ~500 mm³, the animals were injected with three doses of control NPs or reporter NPs (dose equivalent to 15 mg/kg paclitaxel) every alternate day (days 0, 2, and 4). The reporter element concentrations in both control NPs and reporter NPs were kept constant. The live mouse imaging was done at different time points using a Maestro (CRI) in vivo fluorescence imaging system. Representative pictures from the (B) control NP-treated and (C) reporter NP-treated groups at different time points. (D) Graph shows the quantification of tumor response to drug treatment as measured in terms of near-infrared fluorescence intensity ratio between tumor and normal tissues at different time intervals. Representative pictures from the (E) control NP-treated and (C) reporter NP-treated groups at different time points. (D) Graph shows the effect of treatment on 4T1 tumor-bearing mice treated with either control NPs or reporter NPs where tumor growth was quantified as change in relative tumor volume. (F) Representative pictures of tumor-bearing mice imaged at 24 and 48 h after treatment with a combination of either paclitaxel (PTX) + reporter element or PTX-NP + reporter element. Side panels show ex vivo images of the tumor from the tumor bearing mice after the treatments. Lower panels capture fluorescent emission images. (G) [18F]FDG PET and CT images of representative animals in control NPs- and reporter NPs-treated groups before and 12 h after the treatment. The 4T1 breast tumor-bearing mice were treated with reporter NPs (equivalent to 15 mg/kg of paclitaxel) or control NPs (NPs with only the reporter element). (H) Graphs show maximum SUV (SUV max) and % injected dose per mL (% ID/mL) for different treatment groups from the above study. Data represent mean ± SEM (n = 3–10, *P < 0.05, **P < 0.001 vs. corresponding control NP-treated values for that time point, ANOVA followed by Bonferroni’s post hoc test).

In a separate experiment, we studied the biodistribution of the reporter nanoparticles in tumor-bearing mice. As shown in Fig. 5 B–D, the sensitive tumor showed ~400% increase in fluorescence activation compared with resistant tumor, which was detected as early as 12 h after the first treatment. Furthermore, immunolabeling the tumor sections for cleaved caspase-3 confirmed that the mechanism of action of the reporter nanoparticle efficacy and fluorescent signal in sensitive tumor is due to drug-mediated caspase activation (Fig. 5E).

In a separate experiment, we studied the biodistribution of the reporter nanoparticles in tumor-bearing mice. As shown in Fig. 5F, we observed a preferential accumulation of the nanoparticles in the tumor, consistent with the notion that nanoparticles can home in to tumors through an EPR effect (53). We also observed significant concentrations in the liver and the kidney, which could indicate clearance routes. It should be noted that the cutoff for glomerular clearance of nanoparticles is ~5 nm (54),...
indicating that the reporter nanoparticles likely break down into smaller fractions in circulation. We observed minimal accumulation in the major reticuloendothelial organs (RES), including lungs or spleen, consistent with the large hydrodynamic radii as opposed to the actual electron microscopy measurements, which means that the nanoparticles are masked from the RES.

**Reporter Nanoparticles Can Be Extended to Monitoring Immunotherapy Efficacy in Vivo.** We next studied whether the reporter nanoparticle can be adapted to immunotherapy. To engineer a reporter nanoparticle that acts as an immune checkpoint inhibitor, we first derivatized PIMA with different ratio of carboxy-PEG8. As shown in Fig. S7A and B, at an optimal ratio of 1:10, i.e., 10 PEG8 per molecule of PIMA, we obtained defined nanoparticles with a hydrodynamic diameter of 231 ± 22 nm, whereas higher or lower ratios resulted in nanoparticles of larger size. Using the 10:1 PEG to polymer ratio, we next conjugated the reporter element to PIMA, such that the ratio of PIMA:PEG8:reporter element was 1:9:1. The antibody against PD-L1 was then conjugated to the PEG, resulting in nanoparticles that had a hydrodynamic diameter of 242 ± 37 nm. A control IgG-conjugated reporter nanoparticle was similarly engineered and was found to be similar in dimension as the anti-PD-L1-reporter nanoparticle. To test whether the bioconjugation conserves the binding of the antibody to PD-L1, we first treated the B16/F10 melanoma cells with IFNγ for 48 h, which resulted in an overexpression of PD-L1 compared with controls, as quantified using flow cytometry (Fig. S7C). These cells were then incubated with FAM-labeled reporter nanoparticles conjugated with either anti-PD-L1 antibody or control IgG. As shown in Fig. S7D, the anti-PD-L1-reporter nanoparticle was found to bind to the cells to a greater degree compared with the controls.

Having established the binding in vitro, we next tested whether the anti-PD-L1 reporter nanoparticles enabled the monitoring of drug response in real time in vivo. As shown in Fig. 6A and B, compared with the IgG-control reporter nanoparticles, a significant increase in the fluorescent signal was observed by day 5 in the anti--PD-L1 reporter nanoparticles-treated group. This is consistent with the indirect mechanisms of induction of cell death following treatment with an immune checkpoint inhibitor (55). Indeed, Western blotting revealed an increased caspase activation in the cells isolated from the anti-PD-L1 reporter nanoparticles-treated tumor as opposed to the control group (Fig. 6C). Furthermore, quantifying CD44+CD62L+CD8+ve cells in the tumor revealed that the treatment with anti–PD-L1 reporter nanoparticles indeed enhanced activated T cell infiltration by ~200% compared with IgG-reporter nanoparticles (Fig. 6D). We further investigated if [18F] FDG-PET or CT imaging could similarly detect the early treatment response as achieved using the reporter nanoparticles. However, as shown in Fig. 6E and F, we did not observe any reduction in the SUV or [18F] FDG uptake in tumor even at 7-d posttreatment between control nanoparticles and reporter nanoparticles-treated groups.

**Discussion**

The quest for precision medicine is being driven by the development of new technologies. Here we describe the development of a reporter nanoparticle technology platform, which can preferentially deliver an anticancer treatment to the tumor and then monitor its antitumor activity in real time. Such a technology can potentially advance precision medicine by helping identify the responders and nonresponders early on while minimizing adverse effects.
Although the current study builds on the recent developments in theranostics, i.e., nanomaterials comprising of a cytotoxic payload and additionally tagged with a tracer allowed the spatial visualization of nanoparticles in vivo (56, 57), such first-generation theranostic nanoparticles did not report on the efficacy of the nanoparticle-based treatment. The “always on” signal meant that these theranostic nanoparticles could not discriminate between a drug-sensitive and drug-resistant tumor. In contrast, the response-activatable aspect of the reporter nanoparticle is designed to monitor the efficacy of the nanoparticle. Indeed, our results show that the reporter nanoparticles can distinguish between a drug-sensitive and a resistant tumor. Additionally, we observed a greater tumor growth inhibition in vivo with the reporter nanoparticle as opposed to free paclitaxel. Similarly, a greater immunotherapeutic biomarker response in terms of TILs was observed with the PDL1-reporter nanoparticle. Previous studies have shown that cancer nanomedicines preferentially home in to tumors and as a result exert enhanced antitumor efficacy (53, 58). Indeed, the findings from our biodistribution studies are consistent with these previous reports.

Our results demonstrated that an anatomical readout of chemotherapy efficacy, i.e., changes in tumor volume, temporally lagged the quantification of apoptosis as a measure of efficacy. A reliance on the anatomical readout alone would have meant that several doses of the therapy would have been administered before we could detect the nonresponder status of a tumor. Additionally, we observed that the current clinically used techniques for monitoring efficacy, such as FDG-PET or CT, are of limited use in the acute temporal setting. In some of the animals we actually noted a transient increase in FDG uptake, consistent with the flare response seen at the onset of chemotherapy as a result of increased glucose uptake by inflammatory cells and/or energy demand of the apoptosis process (59). Additionally, recent studies have indicated that the oncogene activation status can regulate the internalization of [18F]FDG (60), which can further confound the results with such imaging techniques.

The development of noninvasive molecular imaging techniques to detect apoptosis as a direct readout of chemotherapy activity is thus increasingly gaining momentum, stemming from the limitations of the current technologies in monitoring of early tumor response (61). For example, annexin V-conjugated tracers have been used to detect the exposed phosphatidylserine on the outer leaflet of the cell membrane during apoptosis (62, 63). Similarly, probes have been developed that can monitor caspase activity (35, 64–66). For example, a caspase-3–binding radiotracer, [18F]CMCT-11, was recently used to study the induction of apoptosis by chemotherapeutic agents (67). Similarly, a cell-penetrating TcpQ was recently developed to improve the pharmacokinetic properties and improve delivery of FRET-based caspase probes (68). Additionally, nanoparticles have been used to detect caspase activity (69, 70). Separately, nanoparticles have been used previously to deliver paclitaxel or other cytotoxic agents (71). However, results from the current study indicate that a simple combination of two nanoparticles, one that delivers the drug and the other to detect caspase activity, is not sufficient to monitor anticancer efficacy in real time. This could potentially arise from the fact that the dynamics of apoptosis varies between the type and mechanism of action of anticancer agents and regimens and between patients, and thus, dosing the chemotherapy and the probes in the wrong temporal windows could result in erroneous conclusions about drug efficacy (67). Indeed, it is possible that such an asynchrony existed when the reporter element was coadministered separately with paclitaxel or a paclitaxel nanoparticle. Additionally, in a tumor treated with such a combination, the possibility of any cell being loaded with both elements administered separately remains a stochastic process. Although drug-induced caspase activation is a time-sensitive process, theoretically, constraining the effector and the reporter elements in a single nanostructure ensures that the reporter element is in the same cell to capture the apoptotic process initiated by the effector and thereby achieve maximal detection efficiency.

A significant finding was the possibility of using a reporter nanoparticle to deliver and monitor the efficacy of an immune checkpoint inhibitor. A major concern in immunotherapy is the systemic toxicity as a result of global activation of the immune system (72). The possibility of harnessing a nanoparticle to deliver an immunotherapeutic agent can potentially address this concern given the ability of the nanoparticle to preferentially home to the tumor. Although future studies are necessary to better elucidate this therapeutic opportunity, we did observe that the reporter

---

**Fig. 6.** Reporter nanoparticles enable imaging of immunotherapy response in a B16/F10 melanoma mouse model. (A) Representative images of IgG-reporter NPs and PDL1 reporter NPs treated groups at different days after the initial treatment. The treatments were administered when the tumor volume reached ~100 mm³, and live mice images were captured using a Maestro (CRW) in vivo fluorescence imaging system. (B) Graph shows the quantification of number of activated CD8+ T cells in the isolated lymphocyte population. (C) Western blot showing expressions of caspase-3 and cleaved caspase-3 in tumors treated with different reporter NPs. (D) Representative FACS data from the B16/F10 tumor-bearing mice after different treatments. Left shows percentage of CD8+ vs. CD4+ T cells in the isolated lymphocyte population. Right shows the percentage of activated CD8+ T cells (CD44h/CD62L−). The graph shows quantification of number of activated CD8+ T cells per gram of tumor in different treatments. Data represent mean ± SEM (n = 3, *P < 0.05 vs. corresponding temporal value in IgG-reporter NPs groups, ANOVA followed by Bonferroni post hoc test). (E) Representative animals in IgG reporter NPs- and PDL1 reporter NPs-treated groups before and 3 and 7 d after the treatment. B16/F10 melanoma tumor-bearing mice were treated with IgG reporter NPs or PDL1 reporter NPs. (F) Graphs show SUV max and % ID/mL for different treatment groups from the above study.

---

www.pnas.org/cgi/doi/10.1073/pnas.1603455113
nanoparticle comprising a PD-L1 inhibitor-based effector element did mount an immunogenic response in the tumor and also bound to a greater degree on the cancer cells overexpressing PD-L1. Here we focused on monitoring the efficacy of the delivered immune checkpoint inhibitor. Consistent with the current challenges of imaging the efficacy of immunotherapy in cancer, we observed no differences in the baseline PET/CT signal and the signal from the treated groups even at day 7. In contrast, the reporter nanoparticle was able to detect the efficacy signal, although it should be noted that the detection was delayed compared with the chemotherapeutics-induced response, which highlights the temporal differences between the two treatments. Taken together, these results indicate that a reporter nanoparticle might emerge as a powerful technology in cancer immunotherapy.

Much of the recent advances in nanomedicines are being enabled by the development of novel stimuli-responsive materials (73). Indeed, our results indicate that the stimuli-responsive polymer-based reporter nanoparticles can efficiently deliver a chemotherapeutic agent or an immune checkpoint inhibitor to a cancer cell and capture the resulting spatiotemporal apoptotic event. The ability of the reporter nanoparticles to directly monitor kinetics of the drug-induced apoptosis process in real time, with detectable response at acute time points where current gold standards such as [18F]FDG PET/CT imaging are of limited use, indicates that the reporter nanoparticles not only can enable an early readout of chemotherapy efficacy but also will be useful in monitoring treatment monitoring such as the emerging treatment modality in discordant metabolic flux and anatomical changes (74). A limitation of the current approach is the use of fluorescence-based detection; for clinical translation it will be necessary to design caged radiocontrast dyes that are activated by the response of the cancer cell to the effector element. In the emerging scenario of intrinsic and adaptive resistance, the ability of the reporter nanoparticles to monitor the efficacy of therapy in real time can have a major effect in the management of cancer.

Methods

Cytotoxic Reporter Nanoparticle Synthesis and Characterization. Poly(ethylene-alt-maleic anhydride) (PIMA) was dissolved in Dimethylformamide (DMF). To this, 13.5× molar excess of effector element with 1.5 molar excess of reporter element (with green dye FRET pair) was added. Synthesis of effector and reporter elements is described in SI Appendix. To catalyze the reaction, 1,8-Diazbicyclo[5.4.0]undec-7-ene (DBU) was added. The reaction was stirred for 48 h, at room temperature, in argon atmosphere. The resulting product was dialyzed using a regenerated cellulose dialysis bag with a molecular cutoff of 3.5 kDa. The dialyzed product was then lyophilized to get the nanoparticles. For synthesis of NIR FRET pair labeled reporter nanoparticles synthesis, 1 molar equivalent of PIMA, 14.5 molar equivalent of effector element, and 0.5 molar equivalent of reporter element were used, and the reaction was performed as described above. The polymer construct conjugated with effector element and reporter element was then resuspended in double-distilled water and sonicated for 10 min to get the reporter nanoparticles. Sizing and zeta potential were quantified using a Malvern Nanosizer. Drug concentrations were quantified using an HPLC. The mean particle size and ζ potential of the nanoparticles was measured by Dynamic Light Scattering method using Zetasizer Nano ZS90 (Malvern). One hundred microliters of nanoparticles solution were diluted to 1 mL using DI water, and three sets of 10 measurements each were performed at 90° scattering angle to get the average particle size. The ζ potential was measured using a Zetasizer ZS90 with the nanoparticles diluted in water for measurement according to the manufacturer’s manual. The morphology of the nanoparticles was measured using high-resolution TEM by phosphotungstic acid (PTA) negative staining method. The physical stability of nanoparticles was evaluated by measuring changes in mean particle size and ζ potential during storage condition at 4 °C. To quantify the loading of paclitaxel with HCl degradation assay, 1 mL of reporter nanoparticles and 2 mL of hydrochloric acid were stirred together for 6 h at 50 °C. This was followed by purification using a dichloromethane–water system. The organic layer containing the product was collected and moisture-deprived using sodium sulfate. The resultant solvent was evaporated under vacuum, and the degraded product was dissolved in acetonitrile. It was then analyzed using Analytical HPLC system (Waters). For more details, see SI Appendix.

Engineering an Immunotherapeutic Reporter Nanoparticle. PIMA, Carboxy-PEG, and FAM-DEVD or NIR-DEVD peptide were taken in the molar equivalent ratio (1:9:1) and dissolved in anhydrous DMF along with 20 μL of DBU and stirred under inert conditions for 48 h followed by overnight dialysis using regenerated cellulose membranes (MWCO: 100–5000) and lyophilized later. The conjugates were then resuspended in double-distilled water and sonicated for 10 min to get the nanoparticles. The 0.12 weight equivalents of IgG and PDL-1 antibodies were added separately to each of the nanoparticles along with 2 μg EDC and sulfo-NHS. The mixture was then allowed to incubate on a shaker at 4 °C overnight. The nanoparticles were then passed through a Sephadex-G-25 size exclusion column, and the size was measured by Dynamic Light Scattering method using Zetasizer Nano ZS90 (Malvern). For more details, see SI Appendix.

Cell Viability Assay. The 4T1 and MDA-MB-231 breast cancer cells, 4306 ovarian cancer cells, and LLC lung cancer cells were cultured in DMEM, supplemented with 10% (vol/vol) FBS and 0.1% of Antibiotic-Antimycotic 100× solution (15240–062; Invitrogen). A total of 4 × 104 cells were seeded into 96-well flat-bottomed plates. Free drug or reporter nanoparticles (normalized to equivalent amounts of free drug) were added in triplicate in each 96-well plate at appropriate concentrations and incubated in 5% CO2 atmosphere at 37 °C. After the desired time period of incubation, cells were washed and incubated with 100 μL phenol-red free medium (without FBS) containing 20 μL of the CellTiter 96 Aqueous One Solution reagent (Promega). After 2 h incubation in a 5% CO2 atmosphere at 37 °C, the absorbance in each well was recorded at 490 nm using an Epoch plate reader (Biotek Instruments). Blanks were subtracted from all data, and results were analyzed using GraphPad Prism software (GraphPad).

Activation of Fluorescent Dye in Reporter Element Using Caspase-3 Enzyme. Enzyme assays were performed using a fluorescence spectrophotometer (RF5120PC, Shimadzu, NA). Reporter element (0.05 mM, final concentration) was added and incubated with 1,700 μL of caspase buffer (50 mM NaCl, 50 mM Hepes, 1 mM DTT, 10 mM EDTA, 5% (vol/vol) glycerol, and 0.1% CHAPS, pH 7.2) in a cuvette at 37 °C. Fifty units of cleaved caspase-3 enzyme (AbCam) were incubated in buffer for 20 min at 37 °C. Fluorescence intensity was monitored over time with measurements recorded every 15 min using a Shimadzu Fluorescence Spectrophotometer.

In Vitro Apoptosis Imaging Studies. The 4T1, 4306, and LLC cells were treated with different concentrations of reporter nanoparticles (equivalent to 1, 5, 10, and 20 μM of paclitaxel). At different time intervals starting from hour 0 to 72 h, the cells were counterstained with a LysoTracker dye and imaged using an inverted fluorescence microscope (Eclipse Ti; Nikon Instruments). Uptake of nanoparticles (equivalent to 1 μM of paclitaxel) was monitored by a Nikon Eclipse Inverted microscope. After a series of PBS washes, the sections were probed with anti-rabbit goat mAb Alexa Fluor 594 IgG (1:500; Molecular Probes). Nucleus was stained by 4′,6-diamidino-2-phenylindole (DAPI). Images were obtained using a Nikon Eclipse Ti fluorescence microscope equipped with blue, UV, and green filters for FITC, DAPI, and caspase-3, respectively.

In Vivo Imaging Studies in Drug-Sensitive and Drug-Resistant Tumor Spheroids. Human prostate cancer cells DU-145 (paclitaxel sensitive) and DU-145 TR (paclitaxel resistant) were used to form spheroids using low binding plates as described in manufacturer’s protocol (Corning). The spheroid formation was monitored by a Nikon Eclipse inverted microscope. After the spheroid formation, reporter nanoparticles were added to the spheroids for 24 h. After the incubation period, the spheroids were imaged using confocal microscopy.

In Vivo Efficacy Studies in 4T1 Breast Cancer and Lewis Lung Carcinoma Model. The 4T1 breast cancer cells and Lewis lung carcinoma cells (3 × 105 cells) were implanted s.c. in the flanks of 4-week-old BALB/c female mice and male C57/B16 mice, respectively (weighing 20 g; Charles River Laboratories). The drug treatment was started on day 10 after tumor inoculation. The drug therapy consisted of administration of reporter nanoparticles. The formulation was...
prepared and validated such that 100 μL of reporter nanoparticles contained 15 mg/kg of paclitaxel (administered by tail vein injection). Polymer-reporter element nanoparticles (100 μL) (without any taxanes) administered by tail vein injection were used as a control nanoparticles. The reporter nanoparticles doses were administered on the zeroth, second, and fourth days post-drug treatment. The tumor volumes were measured on every alternate day. The tumor volume was calculated by using the formula $L \times B^2$, where the longest diameter was considered as $L$ and the shortest diameter was considered as $B$, as measured using a Vernier caliper. The tumors were harvested immediately following killing and stored in 10% (vol/vol) formalin or OCT frozen for further analysis. All animal procedures were approved by the Harvard Institutional Use and Care of Animals Committee.

**Ex Vivo Imaging of Drug Efficacy in Lewis Lung Carcinoma Model.** For imaging study, tumor slices (5 μm) were cut after being frozen in OCT medium at Harvard Medical School Core facility. For cleaved caspase-3 imaging, tumor sections were stained with primary cleaved caspase-3 antibody followed by Alexa Fluor 594 secondary antibody. For imaging of 5-FAM dye after cleavage of peptide, the tumor sections were imaged using FITC filter. For TUNEL imaging studies, tumor sections were stained with standard TMR red fluorescent terminal deoxynucleotidyl tranferase-mediated diUTP nick end labeling (TUNEL) kit following the manufacturer’s protocol (in Situ Cell Death Detection Kit, TMR-Red; Roche). Images were obtained using a Nikon Eclipse TE2000 fluorescence microscope equipped with red filter.

**In Vivo Imaging of Drug Efficacy and Toxicity in 4T1 Breast Cancer Model.** The 4T1 breast cancer cells (3 × 10^6 cells) were implanted s.c. in the flanks of 4-wk-old BALB/c female mice (weighing ~20 g; Charles River Laboratories). The drug treatment was started on day 10 after tumor inoculation. The drug therapy consisted of administration of reporter nanoparticles. The formulation was prepared and validated such that 100 μL of reporter nanoparticles contained the NIR FRET pair, DyLight 755 dye and DyLight 766 quencher-based reporter element, and the effector element containing a paclitaxel-equivalent dose of 15 mg/kg (administered via tail vein injection). At desired time points after injections, the in vivo NIR fluorescence images were captured using a Maestro (CRi) in vivo fluorescence imaging system. For details of the imaging, please refer to SI Appendix. Fluorescence data were normalized and quantified using Maestro Software. The Maestro Software was used to conduct spectral unmixing. All animal procedures were approved by the Harvard Institutional Use and Care of Animals Committee.

**In Vivo Imaging of Drug Efficacy and Drug Resistance in Dual Tumor Model.** DU15 prostate cancer cells (1.5 × 10^6 cells) and DU145 TR TK paclitaxel-resistant prostate cancer cells (3 × 10^6 cells) were inoculated in Matrigel (BD Biosciences) in the right and left flanks, respectively, of 4- to 5-wk-old male BALB/c athymic nude mice. The drug treatment with reporter nanoparticles was started when the tumor volume reached 500 mm^3. The formulation was prepared and validated such that 100 μL of reporter nanoparticles contained 15 mg/kg of paclitaxel (administered i.v.). At desired time points after injections, the in vivo NIR fluorescence images were taken using Maestro (CRi) in vivo fluorescence imaging system.

**PET/CT Scanning.** All mice were anesthetized using isoflurane for the radiosotope injection, as well as for the duration of the imaging procedure. A customary protocol for PET imaging was performed, where 0.350-0.400 μCi FDG-F18 was injected retroorbitally 1 h before imaging on the NanoPET/CT (Mediso). Following a 1-h postinjection period, the mice were imaged at the Longwood Small Animal Imaging Facility. PET/CT imaging was performed using a Minerva anesthesia bed on a NanoPET/CT imaging system. First, a 30-min whole body FDG-PET scan was acquired. Following the PET scan, the mice received a 10-min whole-body CT scan on the same instrument. The acquisition software used for all scans was Nucliev v1.07 (invICRO). Counts per minute were obtained and were converted to Bq. To normalize for variability in injected dose, mouse weight, and tumor specific uptake changes, the SUV was calculated using the following formula: (mean activity in tumor in Bq)/(injected activity in Bq)/(mouse weight). All analysis was done on Vivoquant software (invICRO).

**Study of PDL-1 Nanoparticle Internalization in B16 F10 Melanoma Cells in Vitro.** B16 F10 melanoma cells were seeded in a density of 100,000 cells per well in a six-well plate and made to overexpress PDL-1 on their surface by treatment with 100 ng/mL IFN-γ for 48 h. The PIMA-carboxy PEG-FAM DEVD peptide nanoparticles coated with PDL-1 antibody were added to the cells at a final concentration of 25 μM. After 4 h the media was aspirated, and the cells were washed with cold PBS and were collected for flow cytometric analysis. PIMA-carboxy-PEG-FAM DEVD nanoparticles coated with IgG were used as control. FACs analysis was done using Flowio.

**In Vivo Monitoring of Immunotherapy Response in B16F10 Melanoma Model Using Reporter Nanoparticles.** The B16F10 melanoma cells (5 × 10^5 cells) were implanted s.c. in the flanks of 4-wk-old C57BL/6 male mice (weighing ~20 g; Charles River Laboratories). The drug treatment was started on day 10 after tumor inoculation. The drug therapy consisted of administration of PD-L1 reporter NPs and control IgG reporter NPs. The formulation was prepared and validated such that 100 μL of reporter nanoparticles contained the NIR FRET pair, DyLight 755 dye and DyLight 766 quencher-based reporter element, and the effector element containing a PD-L1-equivalent dose of 5 mg/kg (administered via tail vein injection). Control IgG reporter NPs contained same equivalents of reporter element and antibody concentration. Additionally, 10 mg/kg of anti-PD-L1 antibody was injected along with PD-L1 reporter NP. At desired time points after injections, the in vivo NIR fluorescence images were captured using a Maestro (CRi) in vivo fluorescence imaging system. In additional groups treated with PD-L1 reporter NPs and IgG reporter NPs, PET/CT imaging was performed at desired time points. Fluorescence signals were normalized and quantified using Maestro Software. The Maestro Software was used to conduct spectral unmixing. All animal procedures were approved by the Harvard Institutional Use and Care of Animals Committee.

**Flow Cytometric Analysis to Study in Vivo T Cell Infiltration.** Mice treated with IgG and PDL-1 coated nanoparticles were killed 7 d posttreatment. The tumors were then excised and homogenized in serum-free RPMI-1640 media containing 175μM collagenase type I, into a single cell suspension. The T cells were then isolated using Mouse CD90.2 positive selection kit and stained with APC anti-mouse CD4 and FITC anti-mouse CD8a antibodies to study the populations of CD4+ve and CD8+ve T cells. Activated CD8+ve T cell populations were studied by staining the cells with APC Rat anti-mouse CD62L and FITC Rat anti-mouse CD44 antibodies. Antibody dilutions and isotype controls were used according to manufacturer’s protocols.

**Western Blot for Showing Expression of Cleaved Caspase-3 in In Vivo Samples.** Tumor samples from mice that were administered and were sacrificed hours after Passive PET-400 was injected. Tumor samples treated with protease and phosphatase inhibitors. The cellular debris was removed by centrifugation at 20,800 × g, and the supernatant was taken for the experiment. Protein estimation was done by BCA protein assay kit. Thirty micrograms of protein was loaded in each well and probed for caspase-3, cleaved caspase-3, and beta actin proteins. The blot was imaged by G-Box, Syngene.

**Statistics.** The statistical analysis was determined by two-tailed Student’s t test and one-way ANOVA followed by Bonferroni’s post hoc test. P < 0.05 indicated a significant difference.

**ACKNOWLEDGMENTS.** S.S. is supported by a Department of Defense (DoD) Breast Cancer Research Program Collaborative Innovator Grant (W81XWH-09-1-0700), National Institutes of Health Grant R01 (1R01CA135242), a DoD Breakthrough Award (BC132168), and an American Lung Association Innovation Award (LCD-259932-N). A.G. is supported by an American Cancer Society Postdoctoral Fellowship (122854-PF-12-226-01-CDD).